Tag:
SR One
Latest Headlines
Latest Headlines
Merck backs big VC plan in Canada
Merck is joining forces with Lumira Capital to back a new venture fund in Quebec.
GSK stakes $50M Canadian investment fund, betting on early-stage biotech research
GlaxoSmithKline ( $GSK ) wants to do its part to make sure Canada's biotech scene remains vital as drug developers struggle to find capital for early-stage research. The London-based drug giant plans
GSK's VC unit SR One has new chief
There's some new blood at the helm of London-based drug giant GlaxoSmithKline's venture group. Jens Eckstein, previously a venture partner and entrepreneur-in-residence at TVM Capital, has jumped
GSK venture group backs SpringLeaf in $15M round
SpingLeaf Therapeutics has closed a $15 million Series B round of venture capital to advance its first drug-device combination product toward the clinic, with GlaxoSmithKline's ($GSK) venture unit,
Investors pony up $21M for F-star's antibody work
Austria's f-star, which is using its Modular Antibody Technology platform to discover new antibodies, has raised €15 million ($21 million) in new funding. GlaxoSmithKline's venture capital arm
Westphal leaving SR One, concentrating on VC firm
After only a short run at the helm of SR One, GlaxoSmithKline's ambitious venture arm, Dr. Christoph Westphal is on his way out. The co-founder of Sirtris, who helped engineer the sale of the biotech
